Nearly two years after biotechnology stocks began to tumble, executives at small and midsize firms within the space are finally accepting that share prices aren’t bouncing back anytime soon.

With reality setting in, it’s a buyer’s marketplace for firms searching for acquisitions and partnerships, in keeping with most of the pharmaceutical and medical technology executives who gathered at this yr’s


J.P. Morgan


healthcare investor conference, which wrapped up in San Francisco on Thursday.